2023
Mutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment options
2018
Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer
Talsania A, Chiang A. Chapter 7 A Practical Approach to Management of Small Cell Lung Cancer. 2018, 117-129. DOI: 10.1016/b978-0-323-48565-4.00007-2.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerLung cancerLimited stage small cell lung cancerStage small cell lung cancerSecond-line treatment optionAddition of immunotherapyTime of presentationNCCN guidelinesExtensive diseaseImmunotherapy agentsFrontline treatmentCombination therapyTreatment optionsAggressive formSCLC biologyRB1 lossCancerTherapeutic developmentDiseaseWidespread diseasePossible targetsFunction mutationsContributing factorMolecular determinants